Neuropathy & Pain

Preliminary results from a phase III withdrawal-design trial with lacosamide in patients with painful diabetic neuropathy show that lacosamide was statistically significant over placebo in reducing pain scores. SCHWARZ PHARMA plans for regulatory submission during the second half of 2007

GW Pharmaceuticals announced preliminary results of two Phase III studies of Sativex®, its cannabinoid spray medicine, in peripheral neuropathic pain.

C-peptide improves sensory nerve function in type 1 diabetic patients with early-stage diabetic neuropathy.

Duloxetine was linked with modest changes in glycemia in patients with diabetic peripheral neuropathic pain (DPNP), according to the results of 3 randomized trials.

Acording to a report in the November issue of Diabetes Care, Alpha-lipoic acid (ALA) given orally improves symptoms in patients with diabetic polyneuropathy.

Tall people, regardless of whether they have diabetes or not, are at increased risk for peripheral insensate neuropathy.

A portable, automated device accurately detects electrophysiological abnormalities in the sural nerve, indicating diabetic sensorimotor polyneuropathy,

Neuropathies occur in much earlier stages of abnormal glucose metabolism than previously thought.